See more : Simplex Infrastructures Limited (SIMPLEXINF.NS) Income Statement Analysis – Financial Results
Complete financial analysis of iTeos Therapeutics, Inc. (ITOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iTeos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Atlas Financial Holdings, Inc. (AFHIF) Income Statement Analysis – Financial Results
- Polytec Holding AG (PYT.VI) Income Statement Analysis – Financial Results
- C C Land Holdings Limited (1224.HK) Income Statement Analysis – Financial Results
- Smartpay Holdings Limited (SMP.AX) Income Statement Analysis – Financial Results
- RHÖN-KLINIKUM Aktiengesellschaft (RHKJF) Income Statement Analysis – Financial Results
iTeos Therapeutics, Inc. (ITOS)
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 12.60M | 267.63M | 344.78M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| Gross Profit | 11.70M | 266.82M | 344.16M | -535.00K | -611.00K | -505.00K |
| Gross Profit Ratio | 92.87% | 99.70% | 99.82% | 0.00% | 0.00% | 0.00% |
| Research & Development | 113.30M | 97.36M | 59.37M | 29.90M | 19.21M | 17.19M |
| General & Administrative | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Other Expenses | 0.00 | -3.26M | -10.18M | -5.93M | -4.78M | -163.00K |
| Operating Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Cost & Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Interest Income | 31.77M | 11.36M | 78.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.00K |
| Depreciation & Amortization | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| EBITDA | -151.10M | 148.38M | 257.08M | -37.84M | -21.72M | -17.48M |
| EBITDA Ratio | -1,199.69% | 48.72% | 74.16% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.10M | 126.32M | 244.90M | -45.24M | -28.05M | -21.50M |
| Operating Income Ratio | -1,199.69% | 47.20% | 71.03% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 42.07M | 22.41M | 11.56M | 7.15M | 5.71M | 3.46M |
| Income Before Tax | -109.03M | 148.74M | 256.46M | -38.09M | -22.34M | -18.05M |
| Income Before Tax Ratio | -865.66% | 55.58% | 74.39% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.61M | 52.08M | 41.94M | -57.00K | 119.00K | 11.00K |
| Net Income | -112.64M | 96.65M | 214.52M | -38.03M | -22.45M | -18.06M |
| Net Income Ratio | -894.34% | 36.11% | 62.22% | 0.00% | 0.00% | 0.00% |
| EPS | -3.15 | 2.72 | 6.10 | -1.09 | -0.64 | -2.40 |
| EPS Diluted | -3.15 | 2.56 | 5.68 | -1.09 | -0.64 | -2.40 |
| Weighted Avg Shares Out | 35.76M | 35.55M | 35.18M | 35.04M | 35.02M | 7.51M |
| Weighted Avg Shares Out (Dil) | 35.76M | 37.77M | 37.77M | 35.04M | 35.02M | 7.51M |
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will...
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment...
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday.
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones....
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety...
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management...
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data...
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.96 per share a year ago.
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of...
Source: https://incomestatements.info
Category: Stock Reports